Skip to contentC
CV Sciences, Inc.
C
CVSICV Sciences, Inc. Q2 2022 · 10-Q
Revenue$4.14M$4.14M−19.3% vs Q2 2021 Net Income-$2.65M-$2.65MN/M vs Q2 2021 EPS Diluted-$0.03-$0.03N/M vs Q2 2021 Gross Profit$1,270,000−44.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CV Sciences, Inc. · CIK 1510964 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,169,000N/M Free Cash Flowderived-$1,169,000N/M Margins · derivedGross margin30.7%−14.0 pt vs Q2 2021
Operating margin-55.9%+12.5 pt vs Q2 2021
Net margin-64.1%+4.7 pt vs Q2 2021
ended Jun 30, 2022 · filed Aug 15, 2022 · 46 d after period end